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Summary
Objective: Trends in recorded diagnoses of chronic fatigue
syndrome (CFS, also known as ‘myalgic encephalomyelitis’
(ME)) and fibromyalgia (FM) in the UK were last reported
more than ten years ago, for the period 1990–2001. Our
aim was to analyse trends in incident diagnoses of CFS/ME
and FM for the period 2001–2013, and to investigate
whether incidence might vary by index of multiple depriv-
ation (IMD) score.
Design: Electronic health records cohort study.
Setting: NHS primary care practices in the UK.
Participants: Participants: Patients registered with general
practices linked to the Clinical Practice Research Datalink
(CPRD) primary care database from January 2001 to
December 2013.
Main outcome measure: Incidence of CFS/ME, FM, post-
viral fatigue syndrome (PVFS), and asthenia/debility.
Results: The overall annual incidence of recorded cases of
CFS/ME was 14.8 (95% CI 14.5, 15.1) per 100,000 people.
Overall annual incidence per 100,000 people for FM was
33.3 (32.8–33.8), for PVFS 12.2 (11.9, 12.5), and for asth-
enia/debility 7.0 (6.8, 7.2). Annual incidence rates for CFS/
ME diagnoses decreased from 17.5 (16.1, 18.9) in 2001 to
12.6 (11.5, 13.8) in 2013 (annual percent change 2.8%
(3.6%, 2.0%)). Annual incidence rates for FM diagnoses
decreased from 32.3 (30.4, 34.3) to 27.1 (25.5, 28.6) in
2007, then increased to 38.2 (36.3, 40.1) per 100,000
people in 2013. Overall annual incidence of recorded
fatigue symptoms was 2246 (2242, 2250) per 100,000
people. Compared with the least deprived IMD quintile,
incidence of CFS/ME in the most deprived quintile was
39% lower (incidence rate ratio (IRR) 0.61 (0.50, 0.75)),
whereas rates of FM were 40% higher (IRR 1.40 (0.95,
2.06)).
Conclusion: These analyses suggest a gradual decline in
recorded diagnoses of CFS/ME since 2001, and an
increase in diagnoses of fibromyalgia, with opposing socio-
economic patterns of lower rates of CFS/ME diagnoses in
the poorest areas compared with higher rates of FM
diagnoses.
Keywords
Chronic fatigue syndrome, myalgic encephalomyelitis, fibro-
myalgia, post-viral fatigue, primary care, general practice,
diagnosis, incidence; fatigue
Introduction
Chronic fatigue syndrome (CFS, also known as myal-
gic encephalomyelitis (ME)) and ﬁbromyalgia (FM)
are chronic diseases that share superﬁcial similarities,
including unknown aetiology and pathophysiology,
varied symptomatology, a wide range of severity,
higher incidence in women, no laboratory test to con-
ﬁrm diagnosis (only to rule out other diagnoses), and
speciﬁc co-morbidities.1,2 Three-quarters of FM
patients report being fatigued,3 and one-ﬁfth of adult
and paediatric CFS/ME patients report widespread
pain.4 Both diseases are debilitating, typically imposing
substantial burdens on patients, carers, and families.5,6
Seven case deﬁnitions for CFS/ME have been used
internationally in clinical practice and research since
the ﬁrst was published in 1988, and these deﬁnitions
have diﬀered mainly in the minimum duration of fati-
gue and the type and number of additional symp-
toms.7 In the UK, guidelines for the diagnosis and
management of CFS/ME were published by the
National Institute for Health and Care Excellence
(NICE) in 2007.8 These deﬁne CFS/ME as persistent
and/or recurrent fatigue of 4 months’ duration, of
new or speciﬁc onset (not lifelong), characterised by
post-exertional malaise, unexplained by other condi-
tions, and accompanied by at least one of a dozen
symptoms, including sleep-wake perturbations, cogni-
tive dysfunction, and muscle and/or joint pain.
Referral to specialist CFS/ME care should be oﬀered
within six weeks for children and young people, within
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3–4 months for adults with moderate symptoms, and
immediately for people with severe symptoms. NHS
specialist CFS/ME services oﬀer patient-centred pro-
grammes aiming to rehabilitate patients by increasing
physical, emotional, and cognitive capacities, whilst
managing the impact of symptoms.8
By contrast, there are as yet no UK national guide-
lines for FM. Criteria deﬁning FM were published in
1990 by the American Royal College of
Rheumatology.9 These were not intended to be used
in clinical practice, and the criteria were modiﬁed in
2011 to improve their clinical utility.10 In essence, FM
should be considered in any patient reporting chronic
multifocal or diﬀuse pain that is not explained by
injury, inﬂammation, or other conditions.11 Care path-
way recommendations for FM patients in the UK
have only recently been published, by the British
Pain Society.12 These focus on non-specialist (primary
care) management of FM, with referral to specialist
care reserved for severely aﬀected patients who do
not respond to treatment. As with CFS/ME, treatment
options tend towards therapies such as Cognitive
Behavioural Therapy (CBT). Pharmacological treat-
ments approved in the USA for treatment of FM do
not have UK approval for FM.11
Trends in the incidence of CFS/ME and FM diag-
noses in the UK were last reported for the period
1990 to 2001, at the end of which there were approxi-
mately 15 CFS/ME and 35 FM cases recorded per
100,000 people.13 Incidence of FM increased dramat-
ically from the mid-1990s to 2001, and CFS/ME
increased from 9% to 26% of all fatigue diagnoses.
Trends in the incidence of CFS/ME diagnoses might
be expected to have changed since 2001, because of
growing awareness and recognition of CFS/ME as a
legitimate disease, and publication of NICE guide-
lines. The aim of the present study was to use nation-
ally representative primary care data to investigate
trends in recorded diagnoses of CFS/ME and FM
in the UK between 2001 and 2013, together with
trends in the incidence of diagnoses related to CFS/
ME – post-viral fatigue syndrome (PVFS) and asthe-
nia/debility – and presentation of fatigue symptoms
at GP consultations. We also wanted to investigate
whether primary care data would reveal variation in
incidence by socioeconomic status, given conﬂicting
evidence from an earlier study based on data from
CFS/ME specialist services in England.14
Methods
Data source
The Clinical Practice Research Datalink (CPRD),
formerly known as the General Practice Research
Database (GPRD), is an anonymised research data-
base aggregating medical records data from partici-
pating general practices across the UK
(approximately 7% of 10,000 practices in 2012).15
Practices contributing to CPRD are broadly repre-
sentative of general practices in the UK in terms of
practice size and geographical distribution, and the
source population (approximately four million
‘active’ patients, i.e. alive and registered with a GP)
is broadly representative of the population of the UK
in terms of age, sex, and ethnicity. GPs enter medical
diagnoses and symptoms as Read codes, a hierarch-
ical coding system used to record clinical informa-
tion. Procedures, prescriptions, and referrals to
secondary care are also recorded, and linkage to
Hospital Episode Statistics (HES) data is available
for around half of the participating practices.
CPRD provides two sets of data quality criteria:
‘up-to-standard’ (UTS) time for practices and
‘acceptability’ for patients. These criteria do not
ensure data quality, but the CPRD recommends
that these measures are used as a ﬁrst step to selecting
research-quality patients and periods of quality data
recording. The UTS date is a practice-based quality
metric based on the continuity of recording and the
number of recorded deaths. The acceptable patient
metric is based on registration status, recording of
events in the patient record, and valid age and
gender. Patients with non-contiguous records or
poor data recording, which thereby raises suspicion
about the validity of that patient’s record, are
excluded. For this study, data were obtained from
the 660 general practices in the UK in the CPRD
from 1 January 2001 to 31 December 2013 whose
recording of data was judged to be UTS, in order
to provide a stable denominator for calculating inci-
dence rates. The study protocol was approved by the
MHRA Independent Scientiﬁc Advisory Committee
(protocol #14_041R).
Study cohort
Diagnoses. Patients were identiﬁed by Read code
(Supplementary Table 1) as having an event – chronic
fatigue syndrome (CFS/ME), ﬁbromyalgia (FM),
post-viral fatigue syndrome (PVFS), or asthenia/
debility diagnosis or referral to a CFS/ME specialist
service – during the study period (1 January 2001 to
31 December 2013). The ‘index event’ was the earliest
event of interest for a patient during the study period
and within the practice’s up-to-standard (UTS)
period and the patient’s UTS registration period.
Patients were required to have at least 12 months of
UTS data prior to the index event. For the purpose of
estimating incidence rates, we considered incident, i.e.
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‘new’, diagnoses to be those index events for which
there were no preceding diagnosis of CFS/ME, FM,
PVFS, or asthenia/debility in the patient’s Clinical
Practice Research Datalink (CPRD) medical record.
Read codes for referral to specialist services were
introduced in 2010. Diagnoses which were made
after a referral and which occurred within the
patient’s UTS period (and for which there was no
prior diagnosis) were treated as incident diagnoses.
Fatigue symptoms. Patients were identiﬁed as having
presented with fatigue if they had one or more events
(per calendar year) with a Read code for a fatigue
symptom during the study period (Supplementary
Table 1). Events must have occurred during the
patient’s registration period and during the practice
UTS period, and patients were required to have at
least 12 months of UTS data prior to the event.
Practice-level socioeconomic status. The Index of
Multiple Deprivation (IMD) score was used as a
measure of socioeconomic status for the practice,
based on its postcode. The IMD is the UK govern-
ment’s oﬃcial measure of deprivation.16 It is a com-
posite score derived from seven domains: income,
employment, health and disability, education skills
and training, barriers to housing and services, crime
and disorder, and living environment.
Statistical analyses
Annual incidence rates (and 95% conﬁdence intervals
(CIs)) of diagnoses and fatigue symptoms were calcu-
lated by summing the number of events during each
calendar year per practice, dividing by the number of
acceptable patients registered during the correspond-
ing year, and then calculating an overall rate and
95% CI per 100,000 patients. ‘Lewis plots’ were
used to verify that requiring patients to have at
least 12 months of UTS data prior to the index
event had removed the excess events, which tend to
occur shortly after a patient has registered with a
practice.17 Trends were analysed using join point
(segmented) regression software (Joinpoint
Regression Program, Version 4.3.1.0 – April 2016;
Statistical Methodology and Applications Branch,
Surveillance Research Program, National Cancer
Institute), which performs segmented regression to
estimate the annual percent change (APC) in inci-
dence rates and the number and location of join
points (points at which trends change).18 Join point
software performs pairwise comparisons of models
diﬀering by one join point to determine the model
with optimum ﬁt to the data series. We allowed a
maximum of three join points (because we had 13
data points in our analysis), and an overall signiﬁ-
cance level of 5% was adopted for the comparisons
of models applied to each data series. The models
incorporate variation using the standard error of
the rate; annual percentage charge for each segment
is estimated by ﬁtting a regression line to the natural
logarithm of the rate, using calendar year as an inde-
pendent variable.19 We calculated incidence rates
stratiﬁed by sex, age group, and IMD quintile, and
we used multivariable negative binomial regression to
estimate adjusted incidence rate ratios (IRR) with
sex, age, IMD quintile, and calendar year as inde-
pendent variables, and robust standard errors to
account for clustering within practices. We included
interaction terms to test for evidence of interaction
between age, sex, and IMD quintile with time, using
calendar year as a continuous linear variable if join
point had indicated a constant trend (no join point)
or using time periods corresponding to the segments
between join points. Negative binomial regression
models were ﬁtted using Stata (StataCorp. 2015.
Stata Statistical Software: Release 14. College
Station, TX: StataCorp LP). We also used the
Joinpoint regression software’s implementation of a
statistical test for parallelism to test for diﬀerences in
trends by age, sex, and IMD quintile, using sex¼ fe-
male, age¼ 40–49 years, and IMD¼middle quintile
(Q3) as reference level.20
Results
Diagnoses and referral events
From the source population in CPRD, 63,683 patients
were deemed to have acceptable data and had at least
one diagnostic index event during the study period. Of
these patients, 48,663 had the event(s) within the prac-
tice UTS period, of whom 42,316 patients had at least
12 months of UTS data prior to the index date. FM
accounted for half of the diagnoses (49.6%), followed
by CFS/ME (23.1%), PVFS (16.3%), and asthenia/
debility (9.9%) (Figure 1).
There were 1196 referrals (for 933 patients) rec-
orded since the relevant Read codes for referral to
specialist CFS/ME services were introduced (2010),
of which 506 were index events. Of these, 11 (2.2%)
coincided with a CFS/ME diagnosis and 192 (36.9%)
led to a diagnosis during the patient’s UTS period:
169/192 (88.0%) CFS/ME; 17/192 (8.9%) FM; and 6/
192 (3.1%) PVFS (Figure 1).
Diagnoses and referrals, preceding events (during
the ﬁrst 12 months of the UTS period or predating
the start of the UTS period), and time between ear-
liest preceding event (if any) and the index diagnosis
or referral, are summarised in Table 1. Overall,
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81.9% (34,677/42,316) of patients had no previously
recorded diagnosis of CFS/ME, PVFS, A/D, or FM
or referral to CFS/ME service in their medical record,
and 12.5% (5276/42,316) had a previous event of the
same type as the index event. The remaining 2363
patients (5.6%) had at least one prior event of a dif-
ferent type to the index event. Lewis plots indicated a
constant rate of diagnoses from the 13th month of the
UTS period onwards (Supplementary Figure 1).
Trends in the incidence of diagnoses
The average annual incidence of recorded cases of
CFS/ME over the whole study period was 14.8
(95% CI 14.5, 15.1) per 100,000 people; for FM,
the annual rate per 100,000 people was 33.3 (32.8,
33.8); for PVFS 12.2 (11.9, 12.5), and for asthenia/
debility 7.0 (6.8, 7.2). Trends in incidence rates of
diagnoses are illustrated in Figure 2 (see
Supplementary Table 2 for incidence rates). Annual
incidence of CFS/ME decreased from 17.5 (16.1,
18.9) in 2001 to 12.6 (11.5, 13.8) in 2013. Annual
incidence of FM decreased from 32.3 (30.4, 34.3) in
2001 to 27.1 (25.5, 28.6) in 2007, and then increased
to 38.2 (36.3, 40.1) per 100,000 people in 2013. CFS/
ME as a percentage of all fatigue diagnoses
(excluding FM) increased from 31.1% in 2001 to
59.9% in 2013, whilst asthenia/debility declined
from 24.8% to 4.8% and PVFS declined from
41.1% to 35.4% (Supplementary Figure 2).
Join point regression analysis indicated constant
(no join point) trends over the study period (2001–
2013) as having the best ﬁt to CFS/ME and PVFS
incidence rates. The annual percent change for CFS/
ME was 2.8% (95% CI 3.6%, 2.0%) and
7.8% (10.1%, 5.5%) for PVFS (Table 2).
Trends in diagnoses of asthenia/debility and FM
each had a best ﬁtted model with one join point:
asthenia/debility diagnoses increased to 2003 and
then declined steeply, at 29.6% (33.9%,
24.9%) per annum; FM diagnoses decreased to
2007 (APC 2.4% (5.3%, 0.7%)) and then
increased by 5.9% (3.1%, 8.8%) per annum to 2013.
Trends in the incidence of fatigue symptoms
Overall annual incidence of recorded fatigue symp-
toms was 2246 (2242 to 2250) per 100,000
people (Figure 3). The incidence of recorded fatigue
symptoms increased from 2001 to 2004 (APC 5.3%
(1.1%, 9.6%)) (Table 2), with the trends in the two
subsequent intervals having conﬁdence intervals
which do not exclude a constant rate (APC¼ 0 at
¼ 0.05).
Figure 1. CPRD patient inclusion flowchart for this study.
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Diagnoses and symptoms by age, sex, and
practice-level socioeconomic status
All diagnoses showed strong evidence of variation by
age and sex, and all except asthenia/debility showed
evidence of variation across practice-level quintiles
socioeconomic status (Table 3). Incidence rates were
higher amongst women, and tended to peak between
ages 30–59 years (Figure 4). Incidence rates of CFS/
ME were 2.4-fold higher among women (incidence
Figure 2. Trends in recorded diagnoses of chronic fatigue syndrome (CFS/ME), fibromyalgia, post-viral fatigue syndrome (PVFS),
and asthenia/debility (2001–2013) (vertical bars indicate 95% CI).
Table 2. Trends in incidence of diagnoses and fatigue symptoms.
Diagnosis/symptoms Period 1
Annual percent
change (95% CI) Period 2
Annual percent
change (95% CI) Period 3
Annual percent
change (95% CI)
Asthenia and
debility
2001–2003 27.2
(14.8, 90.0)
2003–2013 29.6
(33.9, 24.9)a
CFS/ME 2001–2013 2.8
(3.6, 2.0)a
Fibromyalgia 2001–2007 2.4
(5.3, 0.7)
2007–2013 5.9
(3.1, 8.8)a
Post-viral fatigue
syndrome
(PVFS)
2001–2013 7.8
(10.1, 5.5)
Fatigue symptoms 2001–2004 5.3
(1.1, 9.6)a
2004–2009 1.0
(1.1, 3.3)
2009–2013 1.7
(3.9, 0.5)
Evidence that annual percent change is greater than or less than zero at ¼ 0.05.
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rate ratio (IRR) 2.35 (95% CI 2.19, 2.53)), with peak
incidence in the 40–49 years age group (IRR 1.64
(1.48, 1.83), compared with <20 years age group).
Women had six-fold higher incidence of FM (IRR
6.13 (5.50, 6.82)), peaking between ages 40 and 49
years (IRR 25.3 (20.6, 31.1), compared with ages
<20 years). Social patterns were in the opposite dir-
ections for CFS/ME and FM, with CFS/ME inci-
dence being lowest and FM incidence tending to be
higher in the two most deprived IMD quintiles
(Figure 5). The incidence rate ratios comparing the
bottom (most deprived) versus the top (least
deprived) IMD quintile were IRR 0.61 (0.50, 0.75)
for CFS/ME, IRR 1.40 (0.95, 2.06) for FM (Table 3).
There were no interactions (all p 0.2) between
age, sex, IMD, and CFS/ME diagnostic incidence.
However, there was weak evidence (test for parallel-
ism p 0.1) of a less steep downward trend in CFS/
ME incidence in male compared with female patients,
and in age groups 20–29 years and 30–39 years com-
pared with 40–49 years (Figure 6, Supplementary
Table 3). CFS/ME incidence in patients age< 20
years followed a diﬀerent trend to other age groups
(p< 0.001), decreasing from 2001 to 2006, then
increasing from 2006 to 2011. There was strong evi-
dence of interaction (p< 0.001) between age and FM
incidence and between sex and FM incidence, but
there was no interaction with IMD (p¼ 0.2). The pat-
tern of a pre-2007 decrease followed by a post-2007
increase was evident only among female patients,
with male patients instead showing a steady decline
(test for parallelism p¼ 0.002) (Figure 6,
Supplementary Table 4). Similarly, the pre-/post-
2007 pattern was apparent among patients in the
30–39, 40–49, and 50–59 year age groups, whereas
there was a constant increase (no join point) in inci-
dence in patients aged <20 and 20–29 years and a
constant decrease in incidence in patients age 60–69
and 70þ years.
Discussion
Statement of principal findings
Our study has shown that the incidence of CFS/ME
diagnoses declined over the period 2001–2013,
whereas FM diagnoses (after an initial decline)
showed an overall increase. Asthenia and debility
became almost extinct as diagnostic labels, having
begun the decade on a par with CFS/ME.
Diagnoses of post-viral fatigue syndrome (PVFS)
also fell steeply, to one-third of the incidence in
2001. Clearly, the decline in asthenia/debility and
PVFS diagnoses did not translate into an increase
Figure 3. Trends in fatigue symptoms (2001–2013) (vertical bars indicate 95% CI).
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Figure 5. Recorded diagnoses of chronic fatigue syndrome (CFS/ME), fibromyalgia, post-viral fatigue syndrome (PVFS), and
asthenia/debility by Index of Multiple Deprivation (IMD) quintile (vertical bars indicate 95% CI).
Figure 4. Recorded diagnoses of chronic fatigue syndrome (CFS/ME), fibromyalgia, post-viral fatigue syndrome (PVFS), and
asthenia/debility by age (vertical bars indicate 95% CI).
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in CFS/ME diagnoses. We had anticipated a change
in overall trends in CFS/ME diagnoses after the pub-
lication of NICE guidelines in 2007, but none was
apparent (although cases in patients <20 years old
increased from 2006 to 2011). FM diagnoses
increased markedly from 2007 onwards, levelling oﬀ
from 2011 to 2013 at an annual incidence rate of 40
per 100,000. This is roughly three times higher than
the incidence of CFS/ME. As expected, incidence
rates of CFS/ME and FM were higher amongst
women and peaked between ages 30 and 59 years.
Incidence of CFS/ME showed a strong social gradi-
ent, with lowest incidence in the bottom (most
deprived) socioeconomic quintile, whereas FM had
lower incidence in the top (least deprived) quintile.
Strengths and limitations of the study
The main strength of our study is that it uses CPRD
data, comprising the medical records of approxi-
mately four million ‘active’ patients (alive and regis-
tered with a GP), or 7% of the UK population.15
CPRD patients are representative of the UK popula-
tion, and the data are subject to external and internal
quality control. Active patients have a median of 9.4
years (IQR 3.4–13.9) of data,15 which gives us some
(but not absolute) conﬁdence in classifying diagnoses
as ‘incident’ if the patient’s medical record has no
previously recorded diagnoses.
One limitation of our study is that we examined
recorded data rather than actual incidence, i.e. we are
describing incidence rates of GPs’ recording of diag-
nostic codes. This will have missed cases not recog-
nised by the GP, recognised but not entered into the
clinical records, and recognised but entered into the
records as free text. Another limitation is that diag-
noses were not independently validated. We know
from studies in specialist services that CFS/ME is
frequently misdiagnosed in primary care.21 In 2005,
48% of GPs in one English region did not feel conﬁ-
dent about making a diagnosis of CFS/ME, and 28%
did not recognise CFS/ME as a legitimate illness.22
Although knowledge and awareness of CFS/ME in
primary care had improved towards the end of our
Figure 6. Trends in recorded diagnoses of chronic fatigue syndrome (CFS/ME) and fibromyalgia (2001–2013) by sex, age, and
Index of Multiple Deprivation (IMD) quintile.
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study period,23 non-specialist clinicians still experi-
enced diﬃculty and lack of conﬁdence in making a
diagnosis of CFS/ME.24
Our data do not tell us whether diagnoses were
made by GPs, or recorded in patients’ medical records
following a specialist consultation. Read codes for
referral to specialist services were only introduced in
2010, limiting our ability to explore this aspect of the
CFS/ME diagnostic pathway. However, our esti-
mated incidence of new CFS/ME diagnoses for the
period 2008–2010 (in 2009, 14.5 (95% CI 13.6 to
15.8) per 100,000) is not inconsistent with estimates
based on data from NHS specialist CFS/ME services
in England (in 2009, 22 (95% CI 17 to 29) per
100,000), if we consider that the latter ﬁgure includes
re-referrals.14 Incidence of CFS/ME diagnoses in 2009
from our data, including patients who had a previ-
ously recorded CFS/ME diagnosis, is 17.0 (95% CI
15.8 to 18.3). This consistency with estimates from
clinical services would suggest that the majority of
patients who have a CFS/ME diagnosis recorded by
their GP have had this diagnosis made or conﬁrmed
by a specialist service. Our overall annual incidence
rate estimate of 14.8 (95% CI 14.5 to 15.1) per
100,000 is also consistent with a rate of 15 (95% CI
6 to 41) per 100,000 reported for the period 2007–2010
based on data from a primary care cross-
sectional study in three English regions.25 These com-
parisons suggest that we can have reasonable conﬁ-
dence in the validity of CFS/ME diagnoses in CPRD
records. During the early part of our study period,
trends in fatigue symptoms appeared to parallel the
underlying CPRD population denominator. This sug-
gests a degree of artefact, for which we could ﬁnd no
explanation. Similarly, the two ‘spikes’ in asthenia/
debility (in 2003) and PVFS (in 2009) are possibly
artefactual, because we are not aware of any drives
to enhance entry of these codes on GP systems. One
possible explanation for the spike in PVFS cases is the
2009 ﬂu pandemic, which started in May 2009 and
continued in waves until the summer of 2010.26
Our study in relation to other studies
The overall decline in ‘fatigue’ diagnoses (CFS/ME,
PVFS, and asthenia/debility) continues the downward
trend (a 44% decrease) reported for the period 1990–
2001 using data from the same source (then called the
General Practice ResearchDatabase (GPRD)).13 As in
our study, this trend was set against a backdrop of no
overall change in incidence of fatigue symptoms. This
earlier study also showed the emergence in the mid
1990s of ﬁbromyalgia as a diagnosis, which the authors
ascribed to fashions in diagnostic labelling rather than
to a true increase in incidence.13 In addition to
publication of NICE guidelines, the period covered
by our study witnessed a growth in NHS specialist
CFS/ME service provision across England,27 such
that 140 of 152 Primary Care Trusts (PCTs) had com-
missioned a specialist service by 2010 (PCTs were abol-
ished in 2013 during a reorganisation of theNHS).14 In
the context of these changes, the steady decline in CFS/
ME diagnoses is perplexing. In the absence of curative
treatments and, given that we have no reason to suspect
underlying trends in the causal agents and risk factors
for CFS/ME (or PVFS), we cannot discount a trend in
diagnostic labelling. However, the decline does not
show any sudden ﬂuctuations and does not correlate
with declines in alternative diagnoses (PVFS and asth-
enia/debility), suggesting that itmay reﬂect a real trend.
Although specialist service provision for paediatric
CFS/ME in the UK is geographically much less com-
prehensive than for adults, with many barriers to
accessing the few available services,28 the prognosis
for natural recovery in children and young people is
better than in adults.29 Also, guidelines for the man-
agement of paediatric CFS/ME were published by the
Royal College of Paediatrics and Child Health in
2004.30 We note that the observed annual incidence
for patients <20 years of age (10 per 100,000) trans-
lates into a prevalence of 1–2% (if we assume an
average 12–24 months’ duration of illness), which is
entirely consistent with paediatric CFS/ME preva-
lence estimates from population-based studies.31
We would expect that a substantial proportion (if
not all) PVFS cases should have been classiﬁed as
CFS/ME. Viral infections are known to trigger CFS/
ME,32 and fatigue of 4 months’ duration after the
acute phase of an infection has passed should, accord-
ing to NICE criteria, warrant consideration for a diag-
nosis of CFS/ME.8 Towards the end of our study
period, this reclassiﬁcation would increase the inci-
dence of CFS/ME by around 50%, but the trend in
CFS/ME diagnoses would still be downwards.
Population-wide incidence of CFS/ME in Norway
from 2008 to 2012 as indicated by ICD-10 code
G93.3 (‘post-viral fatigue syndrome/benign myalgic
encephalomyelitis’) was 25.8 (25.2, 26.5) per 100,000
person years.33 This is 74% higher than the incidence
in our study, possibly because the ICD-10 code com-
bines PVFS and CFS/ME in a single classiﬁcation.
Whether the levelling out of incident FM diag-
noses towards the end of our study period represents
a plateau reﬂecting true incidence remains to be seen.
The three-fold higher incidence of FM compared
with CFS/ME is supported by prevalence estimates,
which show that the prevalence of FM (1–5%,
depending on classiﬁcation criteria)34 is several
times higher than the prevalence of CFS/ME (0.8%
(95% CI 0.2% to 1.3%) from a meta-analysis of
Collin et al. 241
prevalence studies based on clinically conﬁrmed
cases).35 In adults, both are long-term conditions
with poor prognosis and limited therapeutic
options.36,37 The evidence base for CFS/ME thera-
pies is arguably stronger than for FM,1 but a range
of pharmacological agents are available (albeit
unsupported by strong evidence of eﬀect) for symp-
tom control in FM.11,38 These include three drugs
approved in the USA during the period of our
study (pregabalin in 2007, duloxetine in 2008, and
milnacipran in 2009). The absence of UK approval
for these drugs means that we cannot ascribe the
post-2007 increase in FM incidence to GP’s being
more willing to diagnose FM because of the availabil-
ity of prescription drugs for FM.
The age and sex distributions of CFS/ME and FM
are well-documented,1,3,33,34 socioeconomic variation
less so. We know that childhood social adversity
increases the risk of CFS/ME in children and adoles-
cents,31 and that this increased risk may persist into
adulthood.39 Evidence for a link between social
adversity in adulthood and risk of CFS/ME is per-
haps less convincing, more likely to be confounded by
variation in risk, e.g. across ethnic groups, and more
susceptible to selection bias, e.g. by access to health-
care, but the overall pattern suggests higher risk
among lower socioeconomic groups. In an analysis
of patient postcode data from seven CFS/ME special-
ist services in England, we showed that assessment
rates in three of the services were 39–44% lower in
the bottom (most deprived) compared with the top
(least deprived) IMD quartiles,14 which is consistent
with the 39% lower diagnostic incidence that we
reported, comparing the bottom with the top IMD
quintile. There was no social pattern in the other four
services, a discrepancy which we attributed partly to
variation in the ethnic minority composition of the
communities served by the services. Obstacles to
accessing specialist care provide the most likely
explanation for decreasing CFS/ME diagnostic inci-
dence with increasing social deprivation, if we assume
that the well-documented diﬃculties experienced by
people seeking diagnosis and/or specialist treatment
for CFS/ME are more acute for people who have
limited resources.6,23,28
That FM diagnoses showed the opposite trend
requires a diﬀerent explanation, although we note
that the social pattern was for the top (least deprived)
quintile to have lower incidence than the other four
quintiles, each of which had similar incidence with
only weak evidence for the bottom (most deprived)
quintile having the highest incidence. As with CFS/
ME, evidence suggests higher risk of pain disorders
such as FM among lower social classes.40,41 One pos-
sible explanation for the diﬀerent pattern seen for FM
compared with CFS/ME could be that FM is more
likely to be diagnosed andmanagedwithin the primary
care setting; not becauseGPs aremore conﬁdent about
diagnosing and managing FM, but because there are
no specialist services. Indeed, the British Pain Society
care pathway recommends primary care management
of FM, with referral to specialist care only for severely
aﬀected patients who do not respond to treatment.12
Another explanation could be that GPs respond more
decisively to the deﬁning symptom of FM (pain) in
patients who are likely to be presenting with other
symptoms and co-morbidities,40 whereas the cardinal
symptoms of CFS/ME present a more complex and
less-speciﬁc diagnostic picture, further complicated
by CFS/ME-related co-morbidities such as pain and
mood disorders.4 This argument is strengthened by the
observation that patients with FM and lower socio-
economic status reported greater symptom severity
and functional impairment,42 although this pattern
has also been observed in community-based samples
of people diagnosed with CFS/ME.43
Unanswered questions and future research
The strong evidence for a social gradient in CFS/ME
diagnoses, contrary to evidence indicating that inci-
dence should if anything be higher at lower socioeco-
nomic levels, raises a question which can perhaps
only be answered by collecting prospective data at
primary care level, supplemented by qualitative
research into the diagnostic and referral process for
patients across diverse social and ethnic groups. Most
CFS/ME specialist services report anecdotally that
black and minority ethnic groups are underrepre-
sented among their service users, despite CFS/ME
possibly being more prevalent in UK ethnic minori-
ties,44 but the extent to which this disparity reﬂects
diﬀerences in cultural norms or professional practice
is unknown.45 This aspect of CFS/ME care provision
requires investigation, something which should
become possible as collection of ethnicity data
within CPRD improves.46
Conclusions
Our study has provided an up-to-date picture of
trends in the incidence of CFS/ME and FM diag-
noses, indicating an ongoing need to provide care
pathways and commission specialist services for
these relatively common and debilitating long-term
conditions. In addressing this need, two salient fea-
tures of our ﬁndings need to be taken into account,
namely: (1) that the incidence of FM is three times
higher than incidence of CFS/ME, yet there are no
national guidelines for the diagnosis and
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management of FM and (2) that the incidence of
CFS/ME diagnoses appears to be 40% lower in the
most versus least deprived socioeconomic quintile,
despite evidence that CFS/ME should be as
common, if not more common, among people experi-
encing higher levels of social adversity.
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